An HTLV-I/II vaccine: From animal models to clinical trials?

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 13, Issue SUPPL. 1, 1996, Pages

  De Thé, Guy ^a   Kazanji, Mirdad ^a  

^a Institut Pasteur   (France)

Author keywords

Epidemiology; HTLV II; Human T lymphotropic virus type I (HTLV I); Monkey; Rabbit; Rat; Recombinant vaccine; Vaccination

Indexed keywords

RECOMBINANT VACCINE; VIRUS VACCINE;

CONFERENCE PAPER; DRUG INDICATION; DRUG RESEARCH; ENVELOPE GENE; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS 2; HUMAN T CELL LEUKEMIA VIRUS INFECTION; INFECTION PREVENTION; MONKEY; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; VACCINATION; VACCINE PRODUCTION;

ANIMALIA; HTLV; HTLV I; HTLV II; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMAN T-LYMPHOTROPIC VIRUS 2; ORYCTOLAGUS CUNICULUS;

EID: 0029739111     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199600001-00029     Document Type: Conference Paper

References (48)

1. De Thé G, Bomford R. An HTLV-I vaccine: Why, how and for whom? AIDS Res Hum Retroviruses 1993;9:381-6.
2. De Thé G, Bomford R, Kazanji M, Ibrahim F. Human T cell lymphotropic virus: necessity for and feasibility of a vaccine. In: Vaccines against virally induced cancers (Ciba Foundation Symposium 187). Chichester: Wiley, 1994:47-60.
3. Bartholomew C, Blattner W, Cleghorn F. Progression to AIDS in homosexual men coinfected with HIV and HTLV-I in Trinidad. Lancet 1987;2:1469.
4. Page JB, Lai S, Chitwood DD, Klimas NG, Smith PC, Fletcher MA. HTLV-I/II seropositivity and death from AIDS among HIV-I seropositive intravenous drug users. Lancet 1990;335:1439-41.
5. Lentino JR, Pachucki CT, Schaaff DM, et al. Seroprevalence of HTLV-I/II and HIV-1 infection among male intravenous drug abusers in Chicago. J AIDS 1991;4(9):901-9.
6. Hattori T, Koito A, Takatsuki K, et al. Frequent infection with human T-cell lymphotropic virus type I in patients with AIDS but not in carriers of human immunodeficiency virus type 1. J AIDS 1989;2(6):604.
7. Hall WW, Zhu WZ, Novoa P, et al. Human T lymphotropic virus, type II (HTLV-I): epidemiology, molecular properties and clinical features of infection. J AIDS Hum Retroviruses Supplement for Proceeding of Seventh International HTLV Conference 1996.
8. Earl PL, Moss B, Morrison RP, Wehrly K, Nishio J, Chesebro B. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science 1986;234:728-31.
9. Schaller JP, Hoover EA, Olsen RG. Active and passive immunization of cats with inactivated feline oncornaviruses. J Natl Cancer Inst 1977;59:1441-50.
10. Lewis MG, Mathes LE, Olsen RG. Protection against feline leukemia by vaccination with a subunit vaccine. Infect Immun 1981;34:888-94.
11. Osterhaus A, Weijer K, Uyt de Haag F, et al. Serological responses in cats vaccinated with FeLV ISCOM and an inactivated FeLV vaccine. Vaccine 1989;7:137-41.
12. Gilbert JH, Pedersen NC, Nunberg JH. Feline leukemia virus envelope protein expression encoded by a recombinant vaccinia virus: apparent lack of immunogenicity in vaccinated animals. Virus Res 1987;7:49-67.
13. Tartaglia J, Jarrett O, Neil JC, Desmettre P, Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox recombinant, ALVAC-FL. J Virol 1993; 67:2370-5.
14. Kono Y, Arai K, Sentsui H, Matsukawa S, Itohara S. Protection against bovine leukemia virus infection in sheep by active and passive immunization. Jpn J Vet Sci 1986;48:117-25.
15. Gatei MH, Naif HM, Kumar S, et al. Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 cell response to gp51 peptides 51-70. J Virol 1993;67:1803-10.
16. Marx PA, Pedersen N, Lerche N, et al. Prevention of simian acquired immune deficiency syndrome with a formalin-inactivated type D retrovirus vaccine. J Virol 1986;60:431-5.
17. Brody BA, Hunter E, Kluge JD, Lasarow R, Gardner M, Marx PA. Protection of macaques against infection with simian type D retrovirus (SRV-1) by immunization with recombinant vaccinia virus expressing the envelope glycoproteins of either SRV-1 or Mason-Pfizer monkey virus (SRV-3). J Virol 1992;66:3950-4.
18. Hu SL, Zarling JM, Chinn J, et al. Protection of macaques against simian AIDS by immunization with a recombinant vaccinia virus expressing the envelope glycoproteins of simian type D retrovirus. Proc Natl Acad Sci USA 1989;86: 7213-7.
19. Ragot T, Finerty S, Watkins PE, Perricaudet M, Morgan AJ. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoproteins gp 340/ 220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J Gen Virol 1993;74:501-7.
20. Kazanji M, Bessereau JL, Gessain A, Bomford R, de Thé G. Expression of the HTLV-I envelope gene inserted into a recombinant adenovirus. AIDS Res Hum Retroviruses 1994; 10(4):509.
21. Shida H, Tochikura T, Sato T, et al. Effect of the recombinant vaccinia viruses that express HTLV-I envelope gene on HTLV-I infection. EMBO J 1987;6:3379-84.
22. Franchini G, Tartaglia J, Markham P, et al. Highly attenuated HTLV type I env poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits. AIDS Res Hum Retroviruses 1995;11:307-13.
23. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9.
24. Fuller DH, Haynes JR. A qualitative progression in HIV type I glycoprotein 120-specific cytotoxic cellular and humoral immune responses in mice receiving a DNA-based glycoprotein 120 vaccine. AIDS Res Hum Retroviruses 1994;10:1433-41.
25. Ugen KE, Agadjanyan M, Wang B, et al. Elicitation of immune responses in rodents after DNA inoculation with an HTLV-I envelope glycoprotein expressing construct: a model for vaccination efficacy. In: Vaccine. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1995: 129-34.
26. Miyoshi I, Yoshimoto S, Kubonishi I, et al. Infectious transmission of human T-cell leukemia virus to rabbits. Int J Cancer 1985;35:81-5.
27. Cockerell GL, Lairmore MD, Rovnak J, Hartley TM, Miyoshi I. Persistent infection of rabbits with HTLV-I; patterns of anti-viral antibody reactivity and detection of virus by gene amplification. Int J Cancer 1990;45:127-30.
28. Lairmore MD, Roberts R, Frank D, Rovnak J, Weiser MG, Cockerell GL. Comparative biological response of rabbits infected with human T-lymphotropic virus type I isolates from patients with lymphoproliferative and neurodegenerative disease. Int J Cancer 1992;50:124-30.
29. Kataoka R, Takehara N, Iwahara Y, et al. Transmission of HTLV-I by blood transfusion and its prevention by passive immunization in rabbits. Blood 1990;76(8):1657-61.
30. Takehara N, Iwahara Y, Uemura Y, et al. Effect of immunization on HTLV-I infection in rabbits. Int J Cancer 1989; 44:332-6.
31. Noguchi Y, Tateno M, Kondo N, et al. Rat cytotoxic T lymphocytes against human T-lymphotropic virus type I-infected cells recognize gag gene and env gene encoded antigens. J Immunol 1989;143:3737-42.
32. Tanaka Y, Tozawa H, Koyanagi Y, Shida H. Recognition of human T cell leukemia virus type I (HTLV-I) gag and pX gene products by MHC-restricted cytotoxic T lymphocytes induced in rats against syngeneic HTLV-I-infected cells. J Immunol 1990;144:4202-11.
33. Suga T, Kameyama T, Kinoshita T, et al. Infection of rats with HTLV-I: A small animal model for HTLV-I carriers. Int J Cancer 1991;49:764-9.
34. Ishiguro N, Abe M, Seto K, Sakurai H, et al. A rat model of human T lymphocyte virus type I (HTLV-I) infection. I. Humoral antibody response, provirus integration, and HTLV-I-associated myelopathy/tropical spastic paraparesis-like myelopathy in seronegative HTLV-I carrier rats. J Exp Med 1992;176:981-9.
35. Ibrahim F, Fiette L, Gessain A, Buisson N, de Thé G, Bomford R. Infection of rats with human T-cell leukemia virus type I: susceptibility of inbred strains, antibody response and provirus location. Int J Cancer 1994;58:446-51.
36. Yamanouchi K, Kinoshita K, Moriuchi R, et al. Oral transmission of human T-cell leukemia virus type-I into a common marmoset (Callithrix jacchus) as an experimental model for milk-borne transmission. Gann 1985;76:481-7.
37. Nakamura H, Hayami M, Ohta Y, et al. Protection of cynomolgus monkeys against infection by human T-cell leukemia virus type-I by immunization with viral env gene products produced in Escherichia coli. Int J Cancer 1987;40:403-7.
38. Kazanji M, Moreau J-P, Bonnemain B, et al. Inoculation of squirrel monkeys Saimiri sciureus with transformed lymphoid cell lines producing HTLV-I (in preparation).
39. Sawada T, Iwahara Y, Ishii K, Taguchi H, Hoshino H, Miyoshi I. Immunoglobulin prophylaxis against milkborne transmission of human T cell leukemia virus type I in rabbits. J Infect Dis 1991;164:1193-6.
40. Takahashi K, Takezaki T, Oki T, et al. Inhibitory effect of maternal antibody on mother-to-child transmission of human T-lymphotropic virus type I. Int J Cancer 1991;49:673-7.
41. Hino S, Katamine S, Miyamoto T, et al. Association between antibodies to the external envelope glycoprotein and vertical transmission of human T-lymphotropic virus type I. Maternal anti-env antibodies correlate with protection in non-breast-fed children. J Clin Invest 1995;95(6):2920-5.
42. Tanaka Y, Tanaka R, Terada E, et al. Induction of antibody response that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization. J Virol 1994;68(10):6323-31.
43. Baba E, Nakamura M, Ohkuma K, et al. Apeptide-based neutralize human T-cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titres of neutralizing antibodies. J Immunol 1995;154(1):399-412.
44. Kazanji M, de Thé G, Bessereau JL, Schulz T, Shida H, Bomfrod R. Vaccination of rats with recombinant adenovirus 5, DNA plasmids and vaccina viruses containing the HTLV-I env gene. AIDS Res and Hum Retrov (in press).
45. Hakoda E, Machida H, Tanaka Y, et al. Vaccination of rabbits with recombinant vaccinia virus carrying the envelope gene of human T-cell lymphotropic virus type I. Int J Cancer 1995;60:567-70.
46. Dezzuti CS, Frazier FE, HuffL Y, Stromberg PC, Olsen RG. Subunit vaccine protects Macaca nemestrina (pig-tailed macaque) against simian T-cell lymphotropic virus Type I challenge. Cancer Res 1990;50:5687s-91s.
47. Plata F, Langlade-Demoyen P, Abastado JP, Berbar T, Kourilsky P. Retrovirus antigens recognized by cytotoxic T lymphocytes activate tumor rejection in vivo. Cell 1987;48: 231-40.
48. Miyazawa M, Nishio J, Cheseboro B. Protection against Friend retrovirus-induced leukemia be recombinant vaccinia viruses expressing the gag gene. J Virol 1992;66:4497-507.